Trial Profile
An Open Label Randomized Phase II Study of SOM230 and Everolimus in Castrate-Resistant, Chemotherapy-Naive Prostate Cancer Patients.
Status:
Discontinued
Phase of Trial:
Phase II
Latest Information Update: 08 Nov 2021
Price :
$35
*
At a glance
- Drugs Pasireotide (Primary) ; Everolimus
- Indications Adenocarcinoma; Prostate cancer
- Focus Therapeutic Use
- 14 Jul 2015 Planned End Date changed from 1 Jun 2016 to 1 Jun 2018 as per ClinicalTrials.gov record.
- 14 Jul 2015 Status changed from recruiting to discontinued as per ClinicalTrials.gov record.
- 27 Jun 2011 Status changed from not yet recruiting to recruiting as reported by ClinicalTrials.gov.